Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (311-320 of 759) with videos related to

Pageof 76
Sort By:
Blood|January 31, 2009
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyOla Landgren, Robert A Kyle, Ruth M Pfeiffer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facilityGregory J Ahmann, Wee Joo Chng, Kimberly J Henderson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 13, 2023
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA studyShaji Kumar, Angela Dispenzieri, Divaya Bhutani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomesGiovanni Palladini, Angela Dispenzieri, Morie A Gertz, et al.
Blood|June 3, 2006
Immunoglobulin free light chains and solitary plasmacytoma of boneDavid Dingli, Robert A Kyle, S Vincent Rajkumar, et al.
JACC. Heart Failure|August 15, 2021
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOSAngelo Giuseppe Caponetti, Claudio Rapezzi, Christian Gagliardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
JACC. Heart Failure|April 12, 2014
Left ventricular amyloid deposition in patients with heart failure and preserved ejection fractionSelma F Mohammed, Sultan A Mirzoyev, William D Edwards, et al.
Orphanet Journal of Rare Diseases|June 18, 2022
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateAngela Dispenzieri, Teresa Coelho, Isabel Conceição, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Pageof 76

Showing results (311-320 of 759) with videos related to

Sort By:
Pageof 76
Blood|January 31, 2009
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyOla Landgren, Robert A Kyle, Ruth M Pfeiffer, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facilityGregory J Ahmann, Wee Joo Chng, Kimberly J Henderson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 13, 2023
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA studyShaji Kumar, Angela Dispenzieri, Divaya Bhutani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomesGiovanni Palladini, Angela Dispenzieri, Morie A Gertz, et al.
Blood|June 3, 2006
Immunoglobulin free light chains and solitary plasmacytoma of boneDavid Dingli, Robert A Kyle, S Vincent Rajkumar, et al.
JACC. Heart Failure|August 15, 2021
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOSAngelo Giuseppe Caponetti, Claudio Rapezzi, Christian Gagliardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
JACC. Heart Failure|April 12, 2014
Left ventricular amyloid deposition in patients with heart failure and preserved ejection fractionSelma F Mohammed, Sultan A Mirzoyev, William D Edwards, et al.
Orphanet Journal of Rare Diseases|June 18, 2022
Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year updateAngela Dispenzieri, Teresa Coelho, Isabel Conceição, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Pageof 76